Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A california cancer consortium trial

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 33-37

  Lara Jr , Primo N ^a,b   Longmate, Jeff ^c,d   Reckamp, Karen ^c,d   Gitlitz, Barbara ^e   Argiris, Athanassios ^f   Ramalingam, Suresh ^g   Belani, Chandra P ^h   Mack, Philip C ^a   Lau, Derick H M ^a,b   Koczywas, Mariana ^c,d   Wright, John J ⁱ   Shepherd, Frances A ^j   Leighl, Natasha ^j   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d City of Hope   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g EMORY UNIVERSITY   (United States)

^h PENN STATE CANCER INSTITUTE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Bortezomib; Docetaxel; Proteasome inhibition

Indexed keywords

BORTEZOMIB; CREATININE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PROTEASOME INHIBITOR;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMORADIOTHERAPY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CALIFORNIA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRAZINES; TAXOIDS;

EID: 79551527647     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2011.n.004     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
3. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
4. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
5. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
6. Ling YH, Liebes L, Zou Y, et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
7. Mortenson MM, Schlieman MG, Virudachalam S, et al. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004;54:343-53.
8. Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004;95:176-80.
9. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G (2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-54.
10. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-7.
11. Nawrocki ST, Sweeney-Gotsch B, Takamori R, et al. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.
12. Denlinger CE, Rundall BK, Keller MD, et al. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004;78:1207-14; discussion 07-14.
13. Lara PN, Jr, Davies AM, Mack PC, et al. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 2004;31:40-6.
14. Gumerlock PH, Kimura T, Holland WS, et al. Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts. J Clin Oncol 2004;22(14 suppl) (abstract 7144).
15. Mack PC, Davies AM, Lara PN, et al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003;41(1 suppl): S89-96.
16. Lara PN, Jr, Koczywas M, Quinn DI, et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 2006;1:126-34.
17. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase ii study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-33.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexa-methasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
20. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-73.
21. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999;274:22123-6.
22. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-21.
23. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63.
24. Chang JT, Chang GC, Ko JL, et al. Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer 2006;118:317-25.
25. Farneth NC, Holland WS, Kenosi T, et al. Proteasome inhibition with bortezomib (PS-341) in combination with docetaxel (Doc) in prostate cancer (CaP) cells and xenografts. J Clin Oncol 2005;23(16 suppl): 239s (abstract 3192).